05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and gene therapy products in the
nature of injectable biologic preparations for genetic,
neurological, motor neuron, or neuromuscular diseases,
disorders and conditions; pharmaceutical preparations and
gene therapy products in the nature of biological
preparations containing genetic materials for treating
spinal muscular atrophy, loss of motor neurons, muscle
degeneration, muscle weakness, and paralysis; gene therapy
preparation in the nature of biological preparations
containing genetic materials for sustained survival motor
neuron protein expression.
The invention relates to design and therapeutic use of solubilized apyrase polypeptides, pharmaceuticals compositions, therapeutic uses and methods useful for preventing and treating tissue damage.
The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.
The present disclosure relates to improved processes to recover acetonitrile from aqueous and organic waste streams, particularly those generated during oligonucleotide manufacturing processes.
The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/5685 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone having an oxo group in position 17, e.g. androsterone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
7.
SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE
The present disclosure provides PROTAC compounds represented by Formula (A): D-L-DSM (A), or an enantiomer, a diastereoisomer, and/or a pharmaceutically acceptable salt of any one of the foregoing, wherein: DSM is a degradation signaling compound {e.g., an E3 ubiquitin ligase recruitment ligand, such as a CRBN ligand or a VHL ligand) covalently attached to a linker L; L is a linker that covalently attaches DSM to D; and D is a Bcl-xL inhibitor compound of Formula (I) or Formula (II) covalently attached to the linker L: (I); (II) wherein the definitions for the variables are described herein. Also provided are pharmaceutical compositions comprising the PROTAC compounds of the present disclosure and methods of use and methods of making thereof.
The present disclosure provides PROTAC compounds represented by Formula (A): D-L-DSM (A), or an enantiomer, a diastereoisomer, and/or a pharmaceutically acceptable salt of any one of the foregoing, wherein: DSM is a degradation signaling compound {e.g., an E3 ubiquitin ligase recruitment ligand, such as a CRBN ligand or a VHL ligand) covalently attached to a linker L; L is a linker that covalently attaches DSM to D; and D is a Bcl-xL inhibitor compound of Formula (I) or Formula (II) covalently attached to the linker L: (I); (II) wherein the definitions for the variables are described herein. Also provided are pharmaceutical compositions comprising the PROTAC compounds of the present disclosure and methods of use and methods of making thereof.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
An ophthalmic lens defining an optical axis can include: a plurality of annular regions extending in a radial direction away from the optical axis, including a corresponding plurality of echelettes, wherein the plurality of echelettes forms an echelette profile, wherein each the echelette profile includes a staircase profile, wherein each echelette includes a staircase step, wherein, for each staircase step, there are M phase-shift units arranged vertically, wherein M is an integer, wherein each phase-shift unit has a phase height configured to shift the phase of a reference frequency of light by approximately N*2*π, where N is an integer, and wherein the staircase profile forms an irregular staircase.
A laser system includes a laser. The laser is configured to emit electromagnetic radiation in laser pulses. The laser system includes an optical switching device configured to switch between a first condition that allows laser pulses emitted by the laser to be output from the laser system and a second condition that prevents the laser pulses emitted by the laser from being output from the laser system. The laser system includes a pulse picking controller configured to receive inputs from an input device and communicate optical switching control signals to the optical switching device based on the inputs. The pulse picking controller selects at least one of a synchronous firing timer or an asynchronous firing timer. The asynchronous firing timer causes a beginning of a pulse picking cycle to start based on receipt of an input of the inputs.
A61F 9/008 - Methods or devices for eye surgery using laser
H01S 3/10 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating
The invention provides a RAF inhibitor and a MEK inhibitor for combined use in the treatment of a solid tumor, and is based on identifying certain RAS mutations, a method for identifying a patient suffering from a solid tumor for amenability to combined treatment with a RAF inhibitor and a MEK inhibitor, a corresponding method of treatment and related invention aspects or embodiments as described in detail below. The RAS mutations are in codon Q61 or a G13R mutation.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5355 - Non-condensed oxazines containing further heterocyclic rings
The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.
An apparatus for eye surgery may comprise a nozzle having a delivery lumen, an implant bay coupled to the nozzle, an implant disposed in the implant bay, and an actuator coupled to the implant bay. The actuator may comprise a housing, a plunger disposed within the housing, a bore through the plunger, a first coupling proximate to a first end of the plunger, and a second coupling integral to the housing. The bore may be fluidly coupled to the implant bay. The first coupling may be configured to receive a hydraulic driver and fluidly couple a working fluid in the hydraulic driver to the bore. A portion of the plunger may be slidingly disposed through the second coupling. In some embodiments, the second coupling may be configured to retain a drive coupling of the hydraulic driver in a fixed position relative to the housing.
Disclosed herein are systems and methods for compensating for a tilt of an intraocular lens (IOL) and systems and methods for adjusting the IOL. For example, one of the methods can comprise capturing one or more optical coherence tomography (OCT) images of an eye of a subject when the IOL is implanted within the eye of the subject. The method can also comprise generating a fixation target such that the fixation target is visible to the eye of the subject and moving the fixation target until a transverse plane of the IOL is perpendicular or substantially perpendicular to an optical axis of an ophthalmic system. The method can also comprise directing a laser beam generated by a laser of the ophthalmic system at the IOL.
The present disclosure provides methods and kits for treating or preventing an allergic reaction to a food allergen consumed by a human subject with one or more food allergies. In particular, the present disclosure provides prophylactic therapies comprising administration of an anti-IgE antibody at a specific dose to a human subject who is allergic to one or more food allergens.
An apparatus for controlling or metering a viscoelastic material for eye surgery. Such an apparatus may generally comprise a housing having a cylinder; a plunger having at least a portion operable to move within the cylinder; a reservoir; an inlet check; and an outlet check valve fluidly coupled to the reservoir. The inlet check valve may be configured to allow the viscoelastic material into the reservoir at a priming pressure. An actuator can be coupled to the plunger and configured to move the plunger in a first direction to increase the pressure in the reservoir to a delivery pressure that is sufficient to close the inlet check valve and open the outlet check valve. A return spring can be configured to move the plunger in a second direction to decrease the pressure in the reservoir.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
Disclosed are substituted imidazoarenes of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, racemate, enantiomer, diastereomer, or tautomer thereof; a method for manufacturing the compounds disclosed herein, and their therapeutic uses.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise an antibody or an antigen-binding fragment thereof covalently linked to at least one BH3 mimetic through a dual linker and the antigen-binding fragment thereof binds to target antigen CD7. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising at least one BH3 mimetic and methods of making the same are also disclosed.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The invention provides a composite material suitable for making hydrogel contact lenses and especially diffractive inserts to be embedded in hydrogel contact lenses. A composite material of the invention has a relatively high refractive index (RI) and is composed of a hydrogel material and high RI nanoparticles which are distributed in the polymer matrix of the hydrogel material and present in an amount sufficient high to provide the composite material with a high RI but sufficient low to provide the composite material with a light transmissibility of 85% or greater in the range between 450 to 700 nm.
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
19.
EXPERT PANEL MODELS FOR NEURAL NETWORK ANOMALY DETECTION AND THWARTING ADVERSARIAL ATTACKS
A system includes a machine learning (ML) engine in which a data store is coupled to a processing system. The processing system executes code to receive a dataset from the data store, and produces three models each comprising three tests. Each of the tests seeks to detect one of three anomaly types corresponding to each of the models. The processing system performs at least two of the three tests relating to each of the three anomaly types. Separately for each anomaly type, the processing system detects an anomaly when two-out- of-three (2oo3) tests conclude that the anomaly is present in the dataset. The dataset including the flagged anomalies is stored in a data repository. The anomaly is filtered from the dataset. The processing system is configured to use data from the dataset to retrain an existing trained ML model.
Anti-CD74 antibody-drug conjugates are disclosed. The antibody-drug conjugates comprise an anti-CD74 antibody or an antigen-binding fragment thereof covalently linked to two antineoplastic payloads through a dual linker. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/5685 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone having an oxo group in position 17, e.g. androsterone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A laser system includes a laser. The laser is configured to emit electromagnetic radiation in laser pulses. The laser system includes an optical switching device configured to switch between a first condition that allows laser pulses emitted by the laser to be output from the laser system and a second condition that prevents the laser pulses emitted by the laser from being output from the laser system. The laser system includes a pulse picking controller configured to receive inputs from an input device and communicate optical switching control signals to the optical switching device based on the inputs. The pulse picking controller selects at least one of a synchronous firing timer or an asynchronous firing timer. The asynchronous firing timer causes a beginning of a pulse picking cycle to start based on receipt of an input of the inputs.
An apparatus for controlling or metering a viscoelastic material for eye surgery. Such an apparatus may generally comprise a housing having a cylinder; a plunger having at least a portion operable to move within the cylinder; a reservoir; an inlet check; and an outlet check valve fluidly coupled to the reservoir. The inlet check valve may be configured to allow the viscoelastic material into the reservoir at a priming pressure. An actuator can be coupled to the plunger and configured to move the plunger in a first direction to increase the pressure in the reservoir to a delivery pressure that is sufficient to close the inlet check valve and open the outlet check valve. A return spring can be configured to move the plunger in a second direction to decrease the pressure in the reservoir.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
25.
EYE TRACKING FIXATION MONITORING SYSTEMS AND METHODS
Systems and methods for tracking eye movement during a diagnostic procedure include an eye tracker capturing images of an eye, and a control processor configured to detect an eye position and orientation in each of the images, determine an eye fixation position and orientation relative to an optical axis of the eye tracker, estimate eye fixation parameters based at least in part on the determined eye fixation position and orientation, and track the eye position and orientation by analyzing the images to determine the eye position and orientation relative to the eye fixation parameters. The eye fixation parameters may comprise a reference position and orientation of the eye when fixated. A histogram is constructed of detected eye positions and orientations and analyzed to determine an eye fixation position and orientation.
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
A61B 3/14 - Arrangements specially adapted for eye photography
A61B 3/18 - Arrangement of plural eye-testing or -examining apparatus
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing medical information to patients who are taking prescription medication for a cardiovascular condition and who directly enroll in a program in the field of cardiovascular diseases
The Trustees of the University of Pennsylvania (USA)
Inventor
Gill, Saar
Ruella, Marco
Abstract
The invention provides compositions and methods for treating conditions or diseases associated with expression of a target chimeric antigen receptor (CAR) as described herein. The invention also relates to an anti-target CAR specific to the target CAR as described herein, vectors encoding the same, and recombinant T cells comprising the anti-target CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing an anti-target CAR as described herein.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
The invention relates to a pharmaceutical formulation comprising the Active Pharmaceutical Ingredient (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, where, in particular, the pharmaceutical formulation is made by a process comprising wet granulation, direct compression or especially roller compaction, and related invention aspects disclosed herein.
The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
31.
METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
32.
EMBEDDED CONTACT LENS WITH A HIGH REFRACTIVE INDEX INSERT THEREIN
The invention provides a composite material suitable for making hydrogel contact lenses and especially diffractive inserts to be embedded in hydrogel contact lenses. A composite material of the invention has a relatively high refractive index (RI) and is composed of a hydrogel material and high RI nanoparticles which are distributed in the polymer matrix of the hydrogel material and present in an amount sufficient high to provide the composite material with a high RI but sufficient low to provide the composite material with a light transmissibility of 85% or greater in the range between 450 to 700 nm.
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
33.
IMAGING SYSTEM AND METHODS DISPLAYING A FUSED MULTIDIMENSIONAL RECONSTRUCTED IMAGE
A system, method, and apparatus for displaying a fused reconstructed image with a multidimensional image are disclosed. An example imaging system receives a selection corresponding to a portion of a displayed multidimensional visualization of a surgical site. At the selected portion of the multidimensional visualization, the imaging system displays a portion of a three-dimensional image which corresponds to the selected multidimensional visualization such that the displayed portion of the at least one of the three-dimensional image or model is fused with the displayed multidimensional visualization.
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 90/20 - Surgical microscopes characterised by non-optical aspects
G06T 19/00 - Manipulating 3D models or images for computer graphics
G06T 19/20 - Editing of 3D images, e.g. changing shapes or colours, aligning objects or positioning parts
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
H04N 13/204 - Image signal generators using stereoscopic image cameras
Described herein are devices and methods for treating eye conditions. Described is an ocular implant including an elongate member having an internal lumen forming a flow pathway, at least one inflow port communicating with the flow pathway, and at least one outflow port communicating with the flow pathway. The elongate member is adapted to be positioned in the eye such that at least one inflow port communicates with the anterior chamber, at least one outflow port communicates with the suprachoroidal space to provide a fluid pathway between the anterior chamber and the suprachoroidal space when the elongate member is implanted in the eye. The elongate member has a wall material imparting a stiffness to the elongate member. The stiffness is selected such that after implantation the elongate member deforms eye tissue surrounding the suprachoroidal space forming a tented volume.
The disclosure concerns a pharmaceutical composition comprising a 225Ac radiolabeled complex formed by a 225Ac radionuclide, and a target binding moiety linked to a chelating agent; and a bismuth sequestering agent, typically capable of sequestering Bi3+. The disclosure also concerns a method for preparing said pharmaceutical composition.
The Trustees of the University of Pennsylvania (USA)
Inventor
Porter, David L.
Frey, Noelle
June, Carl H.
Lacey, Simon
Chen, Fang
Melenhorst, Jan J.
Taran, Tetiana
Mueller, Karen Thudium
Wood, Patricia
Zhang, Yiyun
Abstract
The invention provides a method of treating an adult subject having a hematological cancer, comprising administering to the subject selected dosage regimens comprising a plurality of immune effector cells expressing a CAR molecule.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
37.
METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g. an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
38.
EXPERT PANEL MODELS FOR NEURAL NETWORK ANOMALY DETECTION AND THWARTING ADVERSARIAL ATTACKS
A system includes a machine learning (ML) engine in which a data store is coupled to a processing system. The processing system executes code to receive a dataset from the data store, and produces three models each comprising three tests. Each of the tests seeks to detect one of three anomaly types corresponding to each of the models. The processing system performs at least two of the three tests relating to each of the three anomaly types. Separately for each anomaly type, the processing system detects an anomaly when two-out-of-three (2oo3) tests conclude that the anomaly is present in the dataset. The dataset including the flagged anomalies is stored in a data repository. The anomaly is filtered from the dataset. The processing system is configured to use data from the dataset to retrain an existing trained ML model.
In certain embodiments, an ophthalmic diagnostics system includes a polarization sensitive optical coherence tomography (PS-OCT) device. The system also includes a memory having executable instructions. The system also includes a processor in communication with the memory and configured to execute the instructions to cause the PS-OCT device to emit polarized light to a measurement location on eye tissue of a patient and generate PS-OCT data based on the polarized light. The processor is further configured to execute the instructions to determine birefringent information for the measurement location based on the PS-OCT data and to determine biomechanics information for the measurement location based on the PS-OCT data. The processor is further configured to execute the instructions to determine a correlation between at least a portion of the biomechanics information and at least a portion of the birefringent information.
In certain embodiments, an ophthalmic diagnostics system includes a polarization sensitive optical coherence tomography (PS-OCT) device. The system also includes a memory having executable instructions. The system also includes a processor in communication with the memory and configured to execute the instructions to cause the PS-OCT device to emit polarized light to a measurement location on eye tissue of a patient and generate PS-OCT data based on the polarized light. The processor is further configured to execute the instructions to determine birefringent information for the measurement location based on the PS-OCT data and to determine biomechanics information for the measurement location based on the PS-OCT data. The processor is further configured to execute the instructions to determine a correlation between at least a portion of the biomechanics information and at least a portion of the birefringent information.
A surgical instrument for ophthalmic surgery includes a handle comprising a distal end and a probe comprising a proximal end coupled to the distal end of the handle. In some embodiments, a micro-structure pattern or a coating is formed on a surface of the probe. The surgical instrument further includes a driver in communication with the probe that is configured to cause vibration of the probe. The micro-structure pattern or coating and the vibration may be configured to reduce adhesion of the probe to a vitreous of an eye.
Intraocular lens loading devices and methods of use. In some embodiment the devices are used to sequentially splay first and second haptics while loading the intraocular lens into a delivery lumen.
The Regents of the University of Colorado, a body corporate (USA)
Inventor
Kahook, Malik Y.
Sussman, Glenn
Zacher, Rudolph F.
Mclean, Paul J.
Atkinson, Robert E.
Abstract
Intraocular lenses (IOLs) that improve lens stability by, for example, increasing anterior-posterior stiffness of the IOL, increasing anterior-posterior dimensions of the IOL and/or increasing contact area with the equator of the bag to resist movement of the IOL as the bag collapses over time. These IOLs may be non-modular (single component) or modular (multiple component). In modular embodiments, the IOL system may include intraocular base and optic components, which, when combined, form a modular IOL.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Autoinjectors sold pre-filled with pharmaceutical preparations for the prevention and treatment of disorders and diseases of the immune system; pharmaceutical preparations for the prevention and treatment of musculoskeletal disorders; pharmaceutical preparations for use in dermatology, rheumatology, oncology, and hematology
52.
ANTI-IL-17A ANTIBODIES AND THEIR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS
The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
53.
SURGICAL INSTRUMENTS HAVING REDUCED ADHERENCE TO VITREOUS
A surgical instrument for ophthalmic surgery includes a handle comprising a distal end and a probe comprising a proximal end coupled to the distal end of the handle. In some embodiments, a micro-structure pattern or a coating is formed on a surface of the probe. The surgical instrument further includes a driver in communication with the probe that is configured to cause vibration of the probe. The micro-structure pattern or coating and the vibration may be configured to reduce adhesion of the probe to a vitreous of an eye.
A medical implant is disclosed. The medical implant includes a body having a first end having a first cross-sectional dimension, a second end having a second cross-sectional dimension, and a tapered portion extending between the first end and the second end. The first cross-sectional dimension is larger than the second cross-sectional dimension. In some embodiments, the body comprises multiple layers.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61K 9/00 - Medicinal preparations characterised by special physical form
B29C 33/38 - Moulds or coresDetails thereof or accessories therefor characterised by the material or the manufacturing process
G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfacesMaterials therefor, e.g. comprising photoresistsApparatus specially adapted therefor
An ophthalmic device includes an optic including an optic axis and a haptic structure coupled with the optic. The haptic structure includes an inner ring comprising a plurality of hinges such that portions of the inner ring reside at different radii from the optic axis. The haptic structure further includes a first loop extending from the inner ring and having two points of connection to the inner ring and a second loop extending from the inner ring and having two points of connection to the inner ring. The second loop is oriented opposite the first loop.
The systems and methods described herein provide improved techniques for displaying imaging markers for verifying biometry. A method includes receiving an indication to initiate a first optical coherence tomography (OCT) scanning of an eye; initiating, based on the received indication, the first OCT scanning of the eye; generating, based on the first OCT scanning, a first OCT image of the eye; detecting, based on the first OCT image, a retinal pigment epithelium (RPE) and a fovea in the eye; based on the detecting, causing a first enhanced OCT image to be displayed to a user, the first enhanced OCT image displaying: a first virtual marker segmenting at least a portion of the detected RPE, and a second virtual marker, where the second virtual marker visually identifies a location of the detected fovea, and where the second virtual marker is a radial line through the location of the detected fovea.
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
A back-up infusion pressure sensor module for use in an ophthalmic surgical console includes a squeeze plate configured to engage with a fluid bag. The back-up infusion pressure sensor module further includes a pressure sensor assembly, having a sensor door and a sensor frame, wherein the sensor door pivots relative to a pin coupled to a top portion of the pressure sensor assembly, configured to cause the sensor door to be biased towards the fluid bag. The pressure sensor assembly comprises a base mounted to the back side of the sensor frame of the pressure sensor assembly, one or more springs, a spring bracket coupled to the one or more springs, and a force sensor in contact with the spring bracket, configured to determine a pressure force against the fluid bag.
A video overlay device for use in surgical settings to overlay surgical parameters from a surgical console over images from a surgical microscope is provided. The device includes a video input port configured to receive image data from a camera and a data port configured to receive a removable storage device storing encrypted WiFi configuration data. The device further includes a WiFi transceiver configured to connect, based on the encrypted WiFi configuration data, to a local WiFi network hosted by a surgical console and receive, from the surgical console, overlay data. The device further includes a processor, configured to generate, based on the image data and the overlay data, combined image data and a video output port configured to send the combined image data to a display.
H04N 7/18 - Closed-circuit television [CCTV] systems, i.e. systems in which the video signal is not broadcast
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
H04L 41/08 - Configuration management of networks or network elements
H04W 4/80 - Services using short range communication, e.g. near-field communication [NFC], radio-frequency identification [RFID] or low energy communication
59.
PRESSURE SENSORS FOR OPHTHALMIC SURGICAL CONSOLES AND CASSETTES
A sensor assembly for sensing fluid pressure in a surgical cassette is provided. The sensor assembly includes a tubing having a first portion and a second portion, a follower assembly operable to engage with a retaining ring of the surgical cassette coupled to the first portion, a collar on the second portion of the tubing operable to fit into a bearing of a pump head of a fluid pump assembly within a surgical console operable to receive the surgical cassette, and a biasing element between the follower assembly and the collar operable to apply a biasing force to the follower assembly to engage the follower with the surgical cassette. The follower assembly includes a follower coupled to a cup and a sensor component.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
G01L 9/00 - Measuring steady or quasi-steady pressure of a fluid or a fluent solid material by electric or magnetic pressure-sensitive elementsTransmitting or indicating the displacement of mechanical pressure-sensitive elements, used to measure the steady or quasi-steady pressure of a fluid or fluent solid material, by electric or magnetic means
60.
PUMP ELASTOMER SEAL ENHANCEMENT FOR SURGICAL CASSETTES
Some embodiments provide a surgical cassette designed for use in ophthalmic surgical procedures, which features a multiple chamber pump elastomer to seal multiple chambers within the device. The elastomer is comprised of a silicone rubber component that incorporates a plurality of grooves on its top face and seal beads on its lower portion. The grooves enable lateral deformation of the silicone rubber under compression, improving the seal of the multiple chambers and reducing or eliminating leak paths, thus enhancing the device's performance. The seal beads, strategically placed on the lower portion of the silicone rubber component, prevent separation and lifting of the pump elastomer at the corners by conforming to the geometry of the corners.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
Embodiments disclosed herein provide a connection detecting system for a surgical console. The connection detection system comprises a port for receiving a connector of a surgical device, an emitter, a detector, and a controller connected to the emitter and the detector. The port comprises a light transmission system comprising a detection zone through which the connector of the surgical device is configured to be disposed when the surgical device is coupled to the surgical console, and a pair of light pipes disposed at opposite ends of the detection zone. The emitter is configured to generate a light for propagation through the light transmission system, and the detector is configured to detect the light propagated through the light transmission system. The controller is configured to determine whether the surgical device is connected to the port based on whether the light is detected by the detector.
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
H01R 13/64 - Means for preventing, inhibiting or avoiding incorrect coupling
A61B 17/00 - Surgical instruments, devices or methods
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
62.
VALVE ASSEMBLIES FOR OPHTHALMIC SURGICAL CASSETTES
Certain embodiments disclosed herein provide a surgical cassette including a housing, one or more retaining rings coupled to the housing, and one or more valve assemblies coupled to the housing by the one or more retaining rings. The one or more valve assemblies configured to control fluid communication between one or more channels within the housing. Each valve assembly includes a valve body having a first end with a first shoulder, a second end with a second shoulder, a cylindrical surface connecting the first shoulder and second shoulder, and an upper valve elastomer. The upper valve elastomer includes a first side configured to engage with the first shoulder of the valve body and a second side configured to engage with the retaining ring to facilitate a fluidic seal at a base of the housing.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
Embodiments disclosed herein provide a surgical cassette including pump assemblies with improved contact between a displacement sensor disposed within a surgical console and a diaphragm disposed within the surgical cassette. Each pump assembly includes a diaphragm retainer ring that provides a sufficient creepage and clearance margin, acts as a lead-in for the displacement sensor, assists in preventing misalignment, and provides robustness for the ultrasonic welding process which couples the diaphragm retainer ring to the surgical console. The diaphragm retainer ring is impregnated with a lubricant so to facilitate seating of the displacement sensor with the cassette. A cantilever portion of the diaphragm retainer ring increases a creepage and clearance margin, as well as increases overall part strength in the event of a collision with the displacement sensor and during ultrasonic welding. An insulator is also provided that further increases the creepage and clearance margin.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
A system and method for visualizing an eye using an optical coherence tomography ("OCT") device includes a controller having a processor and a tangible, non-transitory memory on which instructions are recorded. The OCT device produces an OCT beam defined by an OCT beam axis. The controller is adapted to receive a first dataset captured with the OCT beam axis at a first tilt angle from a first visual axis. The controller is adapted to receive a second dataset captured with the OCT beam axis at a second tilt angle from a second visual axis. A plurality of lens segments is generated based on the first dataset and the second dataset. The controller is adapted to generate a lens profile based in part on the plurality of lens segments.
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
65.
2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY
The present invention relates to compounds of formula (I):
The present invention relates to compounds of formula (I):
The present invention relates to compounds of formula (I):
or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds, as well as methods and uses of these compounds in the treatment of diseases.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
66.
VISUALIZATION OF OCULAR LENS BASED ON TILTED OCT IMAGING
A system and method for visualizing an eye using an optical coherence tomography (“OCT”) device includes a controller having a processor and a tangible, non-transitory memory on which instructions are recorded. The OCT device produces an OCT beam defined by an OCT beam axis. The controller is adapted to receive a first dataset captured with the OCT beam axis at a first tilt angle from a first visual axis. The controller is adapted to receive a second dataset captured with the OCT beam axis at a second tilt angle from a second visual axis. A plurality of lens segments is generated based on the first dataset and the second dataset. The controller is adapted to generate a lens profile based in part on the plurality of lens segments.
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
The present disclosure generally relates to fluid control valves for delivering and/or aspirating fluid during ophthalmic surgeries and procedures. In one embodiment, a valve assembly includes a first portion configured to fluidly couple with a gas supply line and a second portion configured to fluidly couple with a liquid supply line and an infusion line via two or more through channels. The first portion and the second portion are partitioned or separated from each other by a filter having a hydrophobic membrane configured to prevent the flow of liquids therethrough while allowing the free flow of gas. Accordingly, an infusion liquid may flow through the second portion while gases may be simultaneously aspirated through the first portion, without any liquids travelling into the gas supply line. The gas supply line may thus be utilized to vent or purge gases from the infusion line before or during performance of surgical procedures.
Certain embodiments disclosed herein provide an ophthalmic surgical system. The system includes a fluidics module and a controller. The fluidic module includes a surgical cassette bay and one or more indicator lights. The one or more indicator lights correspond to one or more fluidic ports on the fluidics module. The controller includes a memory including executable instructions and a processor. The processor is in data communication with the memory. The processor is configured to execute the instructions to cause the system to: determine that a surgical cassette is coupled to the surgical cassette bay; determine a type of the surgical cassette; illuminate at least one of the one or more indicator lights based on the determined type of the surgical cassette; and extinguish the at least one of the one or more indicator lights upon receiving an input indicating that a fluidic tubing is fluidically coupled with the corresponding fluidic port.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor
69.
APPARATUS FOR PROVIDING COMPRESSION IN OPHTHALMIC SURGICAL CASSETTES AND METHODS OF USE THEREOF
Embodiments herein provide a surgical cassette and surgical console for ophthalmic irrigation or aspiration during a surgical procedure, the surgical cassette comprising a plurality of valve assemblies, wherein each valve assembly comprises a retaining ring coupled to a base of the surgical cassette, and a valve body disposed within a cavity defined within the retaining ring, wherein the retaining ring provides a compression force against the valve body that in turn compresses at least a portion of a sealing material disposed on the valve body against a surface of the base. The surgical console comprises a plurality of valve drive assemblies configured to apply additional compression forces to the valve assemblies of the surgical cassette. The valve drive assemblies may be actuated individually or collectively so as to provide additional compression to selected ones of the plurality of valve assemblies.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
Certain embodiments disclosed herein provide a surgical cassette including a housing, one or more retaining rings coupled to the housing, and one or more valve assemblies coupled to the housing by the one or more retaining rings. The one or more valve assemblies configured to control fluid communication between one or more channels within the housing. Each valve assembly includes a valve body having a first end, a second end, a cylindrical surface connecting the first end and second end, and a valve elastomer. The valve elastomer includes a first side configured to couple the valve elastomer to the second end of the valve body and a second side having a recessed surface configured to engage with the housing to form a seal with a base of the housing and reduce mechanical stress across the valve elastomer during rotation of the valve assembly.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
A surgical system including battery packs, a power subsystem and a controller is provided. The power subsystem is configured to connect at least two battery packs in parallel during a backup mode, disconnect the battery packs in a non-backup mode, and prevent each battery pack from charging one or more other battery packs during parallel operation. The controller is configured to individually charge each battery pack to a power capacity equal to or less than a predetermined power capacity, such as 100Wh.
H02J 7/00 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
H02J 9/06 - Circuit arrangements for emergency or stand-by power supply, e.g. for emergency lighting in which the distribution system is disconnected from the normal source and connected to a standby source with automatic change-over
A61B 17/00 - Surgical instruments, devices or methods
72.
METHOD FOR DETECTING EXTERNAL LIGHT WITHIN OPHTHALMIC SURGICAL CASSETTES
Embodiments disclosed herein provide a surgical console, a surgical cassette, and a method for utilizing an image sensor to acquire grayscale image(s) and an embedded microcontroller to then process the image(s) to decode the barcode and/or determine the current level of fluid within the surgical cassette. The image sensor is utilized to detect external light that comes into the field of view of the image sensor. A software algorithm stored within a microcontroller in the surgical console determines whether the potential is high for external light interference. If there is a high potential for external light interference, an advisory or alarm is generated to warn the user to remove the external light source or to turn the console away from the external light source. Once the user has removed the external light and then cleared the advisory, normal console operations and functions can resume.
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
Embodiments disclosed herein provide a compression system including a squeeze plate, a linkage assembly, and a drive assembly. The squeeze plate is configured to engage with a fluid bag. The linkage assembly comprises a plurality of brackets each coupled to a plurality of linkage sets, where actuation of the linkage assembly causes lateral translation of the squeeze plate. The drive assembly comprises a lead screw disposed through each of the plurality of brackets, an actuator configured to rotate the lead screw to actuate the drive assembly, and a nut assembly coupled to the lead screw and at least one of the plurality of brackets, where the nut assembly is configured to provide a biasing force to maintain a target range of pressure on the fluid bag if the actuator fails.
An apparatus (100) for delivering an implant to an eye using a push rod and hydraulic fluid flow or pressure. An implant may be stored, advanced, and delivered to an eye using hydraulic fluid, which can be stored in the apparatus or a sterile container and delivered through the push rod. The plunger may rigidly advance the implant to a sealed position in a first phase, and then the implant may be advanced into the eye via hydraulic pressure or fluid flow in a second phase.
The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an aqueous moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A back-up infusion pressure sensor module for use in an ophthalmic surgical console includes a squeeze plate configured to engage with a fluid bag. The back-up infusion pressure sensor module further includes a pressure sensor assembly, having a sensor door and a sensor frame, wherein the sensor door pivots relative to a pin coupled to a top portion of the pressure sensor assembly, configured to cause the sensor door to be biased towards the fluid bag. The pressure sensor assembly comprises a base mounted to the back side of the sensor frame of the pressure sensor assembly, one or more springs, a spring bracket coupled to the one or more springs, and a force sensor in contact with the spring bracket, configured to determine a pressure force against the fluid bag.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
The present disclosure generally relates to fluid control valves for delivering and/or aspirating fluid during ophthalmic surgeries and procedures. In one embodiment, a valve assembly includes a first portion configured to fluidly couple with a gas supply line and a second portion configured to fluidly couple with a liquid supply line and an infusion line via two or more through channels. The first portion and the second portion are partitioned or separated from each other by a filter having a hydrophobic membrane configured to prevent the flow of liquids therethrough while allowing the free flow of gas. Accordingly, an infusion liquid may flow through the second portion while gases may be simultaneously aspirated through the first portion, without any liquids travelling into the gas supply line. The gas supply line may thus be utilized to vent or purge gases from the infusion line before or during performance of surgical procedures.
A video overlay device for use in surgical settings to overlay surgical parameters from a surgical console over images from a surgical microscope is provided. The device includes a video input port configured to receive image data from a camera and a data port configured to receive a removable storage device storing encrypted WiFi configuration data. The device further includes a WiFi transceiver configured to connect, based on the encrypted WiFi configuration data, to a local WiFi network hosted by a surgical console and receive, from the surgical console, overlay data. The device further includes a processor, configured to generate, based on the image data and the overlay data, combined image data and a video output port configured to send the combined image data to a display.
H04N 5/272 - Means for inserting a foreground image in a background image, i.e. inlay, outlay
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
H04N 7/10 - Adaptations for transmission by electrical cable
80.
PRESSURE SENSORS FOR OPHTHALMIC SURGICAL CONSOLES AND CASSETTES
A sensor assembly for sensing fluid pressure in a surgical cassette is provided. The sensor assembly includes a tubing having a first portion and a second portion, a follower assembly operable to engage with a retaining ring of the surgical cassette coupled to the first portion, a collar on the second portion of the tubing operable to fit into a bearing of a pump head of a fluid pump assembly within a surgical console operable to receive the surgical cassette, and a biasing element between the follower assembly and the collar operable to apply a biasing force to the follower assembly to engage the follower with the surgical cassette. The follower assembly includes a follower coupled to a cup and a sensor component.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
81.
PUMP ELASTOMER SEAL ENHANCEMENT FOR SURGICAL CASSETTES
Some embodiments provide a surgical cassette designed for use in ophthalmic surgical procedures, which features a multiple chamber pump elastomer to seal multiple chambers within the device. The elastomer is comprised of a silicone rubber component that incorporates a plurality of grooves on its top face and seal beads on its lower portion. The grooves enable lateral deformation of the silicone rubber under compression, improving the seal of the multiple chambers and reducing or eliminating leak paths, thus enhancing the device's performance. The seal beads, strategically placed on the lower portion of the silicone rubber component, prevent separation and lifting of the pump elastomer at the corners by conforming to the geometry of the corners.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
82.
APPARATUS FOR PROVIDING COMPRESSION IN OPHTHALMIC SURGICAL CASSETTES AND METHODS OF USE THEREOF
Embodiments herein provide a surgical cassette and surgical console for ophthalmic irrigation or aspiration during a surgical procedure, the surgical cassette comprising a plurality of valve assemblies, wherein each valve assembly comprises a retaining ring coupled to a base of the surgical cassette, and a valve body disposed within a cavity defined within the retaining ring, wherein the retaining ring provides a compression force against the valve body that in turn compresses at least a portion of a sealing material disposed on the valve body against a surface of the base. The surgical console comprises a plurality of valve drive assemblies configured to apply additional compression forces to the valve assemblies of the surgical cassette. The valve drive assemblies may be actuated individually or collectively so as to provide additional compression to selected ones of the plurality of valve assemblies.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
83.
VALVE ASSEMBLIES FOR OPHTHALMIC SURGICAL CASSETTES
Certain embodiments disclosed herein provide a surgical cassette including a housing, one or more retaining rings coupled to the housing, and one or more valve assemblies coupled to the housing by the one or more retaining rings. The one or more valve assemblies configured to control fluid communication between one or more channels within the housing. Each valve assembly includes a valve body having a first end with a first shoulder, a second end with a second shoulder, a cylindrical surface connecting the first shoulder and second shoulder, and an upper valve elastomer. The upper valve elastomer includes a first side configured to engage with the first shoulder of the valve body and a second side configured to engage with the retaining ring to facilitate a fluidic seal at a base of the housing.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
A surgical system including battery packs, a power subsystem and a controller is provided. The power subsystem is configured to connect at least two battery packs in parallel during a backup mode, disconnect the battery packs in a non-backup mode, and prevent each battery pack from charging one or more other battery packs during parallel operation. The controller is configured to individually charge each battery pack to a power capacity equal to or less than a predetermined power capacity, such as 100 Wh.
H02J 9/06 - Circuit arrangements for emergency or stand-by power supply, e.g. for emergency lighting in which the distribution system is disconnected from the normal source and connected to a standby source with automatic change-over
A61B 17/00 - Surgical instruments, devices or methods
H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
Embodiments disclosed herein provide a compression system including a squeeze plate, a linkage assembly, and a drive assembly. The squeeze plate is configured to engage with a fluid bag. The linkage assembly comprises a plurality of brackets each coupled to a plurality of linkage sets, where actuation of the linkage assembly causes lateral translation of the squeeze plate. The drive assembly comprises a lead screw disposed through each of the plurality of brackets, an actuator configured to rotate the lead screw to actuate the drive assembly, and a nut assembly coupled to the lead screw and at least one of the plurality of brackets, where the nut assembly is configured to provide a biasing force to maintain a target range of pressure on the fluid bag if the actuator fails.
An apparatus for delivering an implant to an eye using a push rod and hydraulic fluid flow or pressure. An implant may be stored, advanced, and delivered to an eye using hydraulic fluid, which can be stored in the apparatus or a sterile container and delivered through the push rod. The plunger may rigidly advance the implant to a sealed position in a first phase, and then the implant may be advanced into the eye via hydraulic pressure or fluid flow in a second phase.
In certain embodiments, an ophthalmic system for examining the eye of a patient includes a detector and computer. The detector detects waves reflected from the eye, and the waves convey information about the eye. The detector then generates a detector signal that communicates the information about the eye. The computer performs a contact lens check by determining a characteristic from the eye information indicating the potential presence of a contact lens. The computer generates a notification warning of the potential presence of a contact lens and instructs an output device to provide the notification.
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
A61B 3/117 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for examining the anterior chamber or the anterior chamber angle, e.g. gonioscopes
Pharmaceutical compositions for oral administration comprising the drug substance (S)-1′-chloro-8-(difluoromethoxy)-8′,8′-difluoro-6-(trifluoromethyl)-7′,8′-dihydro-3H,6′H-spiro[imidazo[1,2-]pyridine-2,5′-isoquinoline], or a pharmaceutically acceptable salt thereof, or a free form thereof are described. Further, processes for preparing said pharmaceutical 5 compositions for oral administration and uses of said pharmaceutical compositions in the manufacture of a medicament are described.
The present invention relates to methods, treatment regimens, uses, kits and therapies for prevention of graft rejection in solid organ transplantation, particularly solid organ xenotransplantation, by administering an anti-CD40 antibody or a combination of an anti-CD40 antibody and an anti-C5 antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/36 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
91.
ASPIRATION AND INFUSION CONNECTION INDICATOR LIGHT FOR VITREORETINAL AND CATARACT SYSTEM
Certain embodiments disclosed herein provide an ophthalmic surgical system. The system includes a fluidics module and a controller. The fluidic module includes a surgical cassette bay and one or more indicator lights. The one or more indicator lights correspond to one or more fluidic ports on the fluidics module. The controller includes a memory including executable instructions and a processor. The processor is in data communication with the memory. The processor is configured to execute the instructions to cause the system to: determine that a surgical cassette is coupled to the surgical cassette bay; determine a type of the surgical cassette; illuminate at least one of the one or more indicator lights based on the determined type of the surgical cassette; and extinguish the at least one of the one or more indicator lights upon receiving an input indicating that a fluidic tubing is fluidically coupled with the corresponding fluidic port.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
A61B 17/00 - Surgical instruments, devices or methods
Embodiments disclosed herein provide a connection detecting system for a surgical console. The connection detection system comprises a port for receiving a connector of a surgical device, an emitter, a detector, and a controller connected to the emitter and the detector. The port comprises a light transmission system comprising a detection zone through which the connector of the surgical device is configured to be disposed when the surgical device is coupled to the surgical console, and a pair of light pipes disposed at opposite ends of the detection zone. The emitter is configured to generate a light for propagation through the light transmission system, and the detector is configured to detect the light propagated through the light transmission system. The controller is configured to determine whether the surgical device is connected to the port based on whether the light is detected by the detector.
Certain embodiments disclosed herein provide a surgical cassette including a housing, one or more retaining rings coupled to the housing, and one or more valve assemblies coupled to the housing by the one or more retaining rings. The one or more valve assemblies configured to control fluid communication between one or more channels within the housing. Each valve assembly includes a valve body having a first end, a second end, a cylindrical surface connecting the first end and second end, and a valve elastomer. The valve elastomer includes a first side configured to couple the valve elastomer to the second end of the valve body and a second side having a recessed surface configured to engage with the housing to form a seal with a base of the housing and reduce mechanical stress across the valve elastomer during rotation of the valve assembly.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
94.
METHOD FOR DETECTING EXTERNAL LIGHT WITHIN OPHTHALMIC SURGICAL CASSETTES
Embodiments disclosed herein provide a surgical console, a surgical cassette, and a method for utilizing an image sensor to acquire grayscale image(s) and an embedded microcontroller to then process the image(s) to decode the barcode and/or determine the current level of fluid within the surgical cassette. The image sensor is utilized to detect external light that comes into the field of view of the image sensor. A software algorithm stored within a microcontroller in the surgical console determines whether the potential is high for external light interference. If there is a high potential for external light interference, an advisory or alarm is generated to warn the user to remove the external light source or to turn the console away from the external light source. Once the user has removed the external light and then cleared the advisory, normal console operations and functions can resume.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
G06K 7/14 - Methods or arrangements for sensing record carriers by electromagnetic radiation, e.g. optical sensingMethods or arrangements for sensing record carriers by corpuscular radiation using light without selection of wavelength, e.g. sensing reflected white light
H04N 23/71 - Circuitry for evaluating the brightness variation
95.
DIAPHRAGM RETAINER RING FOR OPHTHALMIC SURGICAL CASSETTES
Embodiments disclosed herein provide a surgical cassette including pump assemblies with improved contact between a displacement sensor disposed within a surgical console and a diaphragm disposed within the surgical cassette. Each pump assembly includes a diaphragm retainer ring that provides a sufficient creepage and clearance margin, acts as a lead-in for the displacement sensor, assists in preventing misalignment, and provides robustness for the ultrasonic welding process which couples the diaphragm retainer ring to the surgical console. The diaphragm retainer ring is impregnated with a lubricant so to facilitate seating of the displacement sensor with the cassette. A cantilever portion of the diaphragm retainer ring increases a creepage and clearance margin, as well as increases overall part strength in the event of a collision with the displacement sensor and during ultrasonic welding. An insulator is also provided that further increases the creepage and clearance margin.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
An intraocular lens (IOL) configured to support a first optic for functioning as a single lens IOL and configured to support a second optic for functioning as a dual optic IOL. The base includes a first optic for providing a base power. A recess in an anterior rim of the base is configured for positioning a radial extension of a second optic. The geometry of the recess is configured to securely couple to the radial extension to prevent rotation of the second optic relative to the base and prevent tilting of the second optic relative to an optic axis.
The disclosure is directed to novel predictive methods and personalized therapies for treating dry eye disease (DED). Specifically, this disclosure relates to methods of treating a patient having DED by selectively administering a TNFα antagonist, e.g., a TNFα antibody, such as LME636, to the patient on the basis of that patient being genetically predisposed to have a favorable response to treatment with the TNFα antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having DED will respond to treatment with a TNFα antagonist, e.g., a TNFα antibody, such as LME636.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an aqueous moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).
A continuous additive fabrication system comprises a bath of photopolymer resin and a light source assembly having a light source and a motorized variable aperture. The light source assembly is operable to generate a focus point in the bath of photopolymer resin, the shape of the focus point at a curing plane within the bath of photopolymer resin corresponding to the shape of the motorized variable aperture. The continuous additive fabrication system further comprises a platform configured to support a build object and a drive mechanism (coupled to at least one of the platform and the light source assembly) configured to continuously move the curing plane through the bath of photopolymer resin. A size and/or shape of the motorized variable aperture is changed while the curing plane in continuously moved through the bath of photopolymer resin.
B29C 64/135 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified characterised by the energy source therefor, e.g. by global irradiation combined with a mask the energy source being concentrated, e.g. scanning lasers or focused light sources
The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating hidradenitis suppurativa, by employing molecules that inhibit the B-cell activating factor receptor (BAFF-R), such as anti-BAFF-R antibodies.
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
